Denali Therapeutics Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report0 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
+0.40%
vs ±9.8% implied · ×0.04
shaded = implied · ▲▼ = realized
Linked news
Denali Therapeutics has 7 disclosed suppliers and 6 disclosed customers in SEC filings.
SentenceLRRK2 Program Manufacturing Biogen will be responsible for delivering all supplies for clinical trials and commercial production for LRRK2 Products, except that we will deliver such supplies until the point of transition which will be mutually agreed by us and Biogen, but in no event later than commencement of activities to support commercial launch, and in any event we retain manufacturing rights for certain independent clinical activities.
SentenceFor example, under our agreements with F-star and Genentech, the licensors control prosecution and, in the case of F-star and in specified circumstances, enforcement of certain of the patents and patent applications licensed to us.
DNLI 10-Kaccession 0001714899-25-000066
SentenceIn addition, we are required to make contingent payments, to F-star Ltd and the former shareholders of F-star Gamma, up to a maximum amount following completion of the research phase of the F-star collaboration of $243.0 million in the aggregate upon the achievement of certain defined preclinical, clinical, regulatory and commercial milestones.
DNLI 10-Kaccession 0001714899-25-000066
SentenceFor example, in June 2016, we entered into a license agreement with Genentech pursuant to which we received an exclusive license to certain of Genentech's intellectual property relating to our LRRK2 program, including our BIIB122/DNL151 product candidate.
DNLI 10-Kaccession 0001714899-25-000066
SentenceOur existing commitments primarily relate to our obligations under existing lease agreements, and certain clinical and manufacturing agreements, including the DMSA with Lonza Sales AG ("Lonza") for the development and manufacture of biologic products.
DNLI 10-Kaccession 0001714899-25-000066
SentenceIn December 2025, we entered into a synthetic royalty funding agreement with Royalty Pharma plc ("Royalty Pharma"), pursuant to which Royalty Pharma has agreed to provide us with up to $275.0 million in funding in exchange for a 9.25% royalty on future worldwide net sales of tividenofusp alfa, which will cease upon reaching a multiple of 3.0x, or 2.5x if achieved by the first quarter of 2039.
DNLI 10-Kaccession 0001714899-26-000021
SentenceWe currently fund our operations primarily with the proceeds from our follow-on offering completed in October 2022, payments received from our collaboration agreements with Biogen , Sanofi, Takeda, and a strategic private offering transaction completed in February 2024.
SentenceWe currently fund our operations primarily with the proceeds from our follow-on offering completed in October 2022, payments received from our collaboration agreements with Biogen , Sanofi, Takeda, and a strategic private offering transaction completed in February 2024.
SentenceWe currently fund our operations primarily with the proceeds from our follow-on offering completed in October 2022, payments received from our collaboration agreements with Biogen , Sanofi, Takeda, and a strategic private offering transaction completed in February 2024.
SentenceIn connection with our collaboration with Biogen, we also entered into a common stock purchase agreement pursuant to which we sold 13,310,243 shares of our common stock to BIMA for an aggregate purchase price of $465.0 million .
DNLI 10-Kaccession 0001714899-25-000066
Denali Therapeutics Inc.
19.01
Expected move
Inputs8Q avg ±3.1%·×4.52·rich
straddle ±17.6%
spot 18.94exp Nov 20ATM strike 20ATM straddle 3.93IV 103%